A couple of years ago I spoke at a Life Sciences Forum organized by Oracle. The audience was 100-percent life science and IT professionals, but I spoke about the magazine business.
A couple of years ago I spoke at a Life Sciences Forum organized by Oracle. The audience was 100-percent life science and IT professionals, but I spoke about the magazine business. Why? Cynics say because I don’t know enough about science or IT, but really it was more to do with the changes that the magazine market was facing and their relevance to the pharma market.
I won’t get into the woes of magazine publishers here. If you really want to know more read The Chaos Scenario by Advertising Age writer Bob Garfield, or if you don’t have time watch the You Tube video promotion of the book. Both book and video do a great job of describing the implosion of centralized mass media, the rise of digital alternatives and the growing importance of listening to what your customers want.
I only bring my presentation and Mr Garfield up because I was reminded of them by title of the keynote at the iPharmaConnect conference to be held in Philadelphia later this month. Pozen EVP Liz Cermak will be talking about Pharma’s very own Chaos Scenario: the revolution of the traditional pharma commercial model and how “the old model just won’t cut it.”
Liz Cermak says that pharma’s attempts to get brand’s in front of HCPs in any meaningful way, is becoming “highly unlikely” and “unappealing” to customers. Like Bob Garfield talking to dead-tree publishers, she calls on Pharma to “get with the program” and “fish where the fish are.”
Like so many magazine readers, HCPs have gone digital and the internet, not sales people, is their number one source for information. And it’s obvious why - they can get information when they want it, where they want it and how they want it. Patients too.
No one is denying that the challenges in the digital pharma space are enormous, not least the lack of clear regulatory guidance. The good news is that, unlike a couple of years ago, when I was speaking to Oracle’s audience, some major pharma brands are developing their digital IQ and are some real success stories out there for everyone to learn from.
Cernak sees the potential not just the problems. Putting her money where her mouth is, she has formed a digital advisory board at Pozen to bring in ideas from non-pharma brands like Pepsi and Walmart and from digital superstars like Marc Monseau formerly of J&J and Daniel Palestrant of Sermo.
The iPharmaconnect conference takes place in Philadelphia March 26th through 28th.
Peter Houston.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.